Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
11
×
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
ipo
11
×
life sciences
national
national blog main
national top stories
11
×
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boston top stories
indiana blog main
indiana top stories
fda
cancer
novartis
biogen
crispr
eli lilly
startups
celgene
deals
glaxosmithkline
venture capital
abbvie
What
bio
11
×
roundup
11
×
drugs
ipo
life
moves
new
pharmaceutical
science
black
cancer
car
ceo
companies
covid
crispr
diamond’s
fda
gene
medicine
medicines
millions
therapeutics
typically
week
years
acquisitions
activity
allogene
alzheimer’s
announced
appetite
approvals
august
bails
becker
big
billions
biogen
biopharma
Language
unset
Current search:
bio
×
ipo
×
roundup
×
" boston blog main "
×
" national top stories "
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
5 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More